Option Care Health price target raised to $41 from $34 at Barrington

Barrington raised the firm’s price target on Option Care Health (OPCH) to $41 from $34 and keeps an Outperform rating on the shares after the company reported “strong” Q2 results and increased FY23 guidance. Following the failed effort to acquire Amedisys (AMED), which was “a deal disliked by many” Option shareholders, Option Care said that it would focus on “smaller tuck-in” type transactions in the near term and given the ongoing strong momentum in the company’s core infusion business, “we suspect this commentary was well-received by most investors,” the analyst said.